Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | RXDX-105 |
Trade Name | |
Synonyms | AC013773|CEP-32496|Agerafenib |
Drug Descriptions |
Agerafenib (RXDX-105) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199, PMID: 31695841). |
DrugClasses | ABL Inhibitor (pan) 9 ABL1 Inhibitor 8 BCR-ABL Inhibitor 32 BRAF Inhibitor 25 CRAF Inhibitor 12 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 RET Inhibitor 52 VEGFR2 Inhibitor 37 |
CAS Registry Number | 1188910-76-0 |
NCIT ID | C107245 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Crizotinib + RXDX-105 | Crizotinib RXDX-105 | 0 | 0 |
GSK2126458 + RXDX-105 | GSK2126458 RXDX-105 | 1 | 0 |
RXDX-105 | RXDX-105 | 7 | 3 |
RXDX-105 + Trametinib | RXDX-105 Trametinib | 1 | 0 |
RXDX-105 + Volasertib | RXDX-105 Volasertib | 0 | 0 |